Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2006-05-22 14:17:48 UTC |
---|
Update Date | 2023-02-21 17:16:20 UTC |
---|
HMDB ID | HMDB0002329 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Oxalic acid |
---|
Description | Oxalic acid is a strong dicarboxylic acid occurring in many plants and vegetables. It is produced in the body by metabolism of glyoxylic acid or ascorbic acid. It is not metabolized but excreted in the urine. It is used as an analytical reagent and general reducing agent (Pubchem). Oxalic acid (IUPAC name: ethanedioic acid, formula H2C2O4) is a dicarboxylic acid with structure (HOOC)-(COOH). Because of the joining of two carboxyl groups, this is one of the strongest organic acids. It is also a reducing agent. The anions of oxalic acid as well as its salts and esters are known as oxalates (Wikipedia ). Bodily oxalic acid may also be synthesized via the metabolism of either glyoxylic acid or unused ascorbic acid (vitamin C), which is a serious health consideration for long term megadosers of vitamin C supplements. 80% of kidney stones are formed from calcium oxalate. Some Aspergillus species produce oxalic acid, which reacts with blood or tissue calcium to precipitate calcium oxalate. There is some preliminary evidence that the administration of probiotics can affect oxalic acid excretion rates (and presumably oxalic acid levels as well) (Wikipedia ). Oxalic acid is found to be associated with fumarase deficiency and primary hyperoxaluria I, which are inborn errors of metabolism. Oxalic acid is a marker for yeast overgrowth from Aspergillus, Penicillum and/or Candida. Can also be elevated due to exposures from vitamin C or ethylene glycol poisoning. Oxalate is elevated in the urine of children with autism. (PMID: 21911305 ). Oxalic acid has also been identified as a uremic toxin according to the European Uremic Toxin Working Group (PMID: 22626821 ). |
---|
Structure | InChI=1S/C2H2O4/c3-1(4)2(5)6/h(H,3,4)(H,5,6) |
---|
Synonyms | Value | Source |
---|
Ethandisaeure | ChEBI | Ethane-1,2-dioic acid | ChEBI | Ethanedioic acid | ChEBI | H2Ox | ChEBI | HOOCCOOH | ChEBI | Oxalsaeure | ChEBI | Ethane-1,2-dioate | Generator | Ethanedioate | Generator | Oxalate | Generator | Ammonium oxalate | HMDB | Ethanedioic acid dihydrate | HMDB | Ethanedionate | HMDB | Ethanedionic acid | HMDB | Kyselina stavelova | HMDB | Oxaalzuur | HMDB | Oxalic acid 2-hydrate | HMDB | Oxalic acid anhydrous | HMDB | Oxalic acid diammonium salt | HMDB | Oxalic acid dihydrate | HMDB | Acid, oxalic | HMDB | Aluminum oxalate | HMDB | Chromium (3+) oxalate (3:2) | HMDB | Dipotassium oxalate | HMDB | Iron oxalate | HMDB | Magnesium oxalate | HMDB | Magnesium oxalate (1:1) | HMDB | Oxalate, dilithium | HMDB | Oxalate, disodium | HMDB | Oxalate, monohydrogen monopotassium | HMDB | Oxalate, monopotassium | HMDB | Oxalate, potassium | HMDB | Chromium oxalate | HMDB | Dilithium oxalate | HMDB | Manganese (2+) oxalate (1:1) | HMDB | Monosodium oxalate | HMDB | Oxalate, chromium | HMDB | Oxalate, dipotassium | HMDB | Oxalate, magnesium | HMDB | Oxalate, monosodium | HMDB | Oxalate, potassium chromium | HMDB | Oxalate, sodium | HMDB | Potassium oxalate | HMDB | Potassium oxalate (2:1) | HMDB | Diammonium oxalate | HMDB | Disodium oxalate | HMDB | Oxalate, aluminum | HMDB | Oxalate, diammonium | HMDB | Oxalate, ferric | HMDB | Oxalate, monoammonium | HMDB | Potassium chromium oxalate | HMDB | Chromium (2+) oxalate | HMDB | Ferric oxalate | HMDB | Iron (2+) oxalate (1:1) | HMDB | Iron (3+) oxalate | HMDB | Monoammonium oxalate | HMDB | Monohydrogen monopotassium oxalate | HMDB | Monopotassium oxalate | HMDB | Oxalate, iron | HMDB | Sodium oxalate | HMDB | Oxalic acid | KEGG |
|
---|
Chemical Formula | C2H2O4 |
---|
Average Molecular Weight | 90.0349 |
---|
Monoisotopic Molecular Weight | 89.995308552 |
---|
IUPAC Name | oxalic acid |
---|
Traditional Name | oxalic acid |
---|
CAS Registry Number | 144-62-7 |
---|
SMILES | OC(=O)C(O)=O |
---|
InChI Identifier | InChI=1S/C2H2O4/c3-1(4)2(5)6/h(H,3,4)(H,5,6) |
---|
InChI Key | MUBZPKHOEPUJKR-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as dicarboxylic acids and derivatives. These are organic compounds containing exactly two carboxylic acid groups. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Carboxylic acids and derivatives |
---|
Sub Class | Dicarboxylic acids and derivatives |
---|
Direct Parent | Dicarboxylic acids and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Dicarboxylic acid or derivatives
- Carboxylic acid
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Carbonyl group
- Aliphatic acyclic compound
|
---|
Molecular Framework | Aliphatic acyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 189.5 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 220 mg/mL at 25 °C | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatized |
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental GC-MS | GC-MS Spectrum - Oxalic acid GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (2 TMS) | splash10-0002-0900000000-eaa92cf80964dd7d345a | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxalic acid GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (Non-derivatized) | splash10-0002-0900000000-b9206a3a54b5be6f07d9 | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxalic acid GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (2 TMS) | splash10-00dj-9500000000-e5db327eab9e8a2f149e | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxalic acid GC-MS (2 TMS) | splash10-00sl-3910000000-75af6e42d4cc12d798f4 | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxalic acid EI-B (Non-derivatized) | splash10-0006-9000000000-8aef9a64d926571c2de0 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxalic acid GC-EI-TOF (Non-derivatized) | splash10-0002-0900000000-eaa92cf80964dd7d345a | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxalic acid GC-EI-TOF (Non-derivatized) | splash10-0002-0900000000-b9206a3a54b5be6f07d9 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxalic acid GC-EI-TOF (Non-derivatized) | splash10-00dj-9500000000-e5db327eab9e8a2f149e | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxalic acid GC-MS (Non-derivatized) | splash10-00sl-3910000000-75af6e42d4cc12d798f4 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxalic acid GC-EI-TOF (Non-derivatized) | splash10-0002-0900000000-3cee49bf06349fbe625e | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Oxalic acid GC-MS (Non-derivatized) - 70eV, Positive | splash10-000f-9000000000-f5e8094c68372ab25a63 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Oxalic acid GC-MS (2 TMS) - 70eV, Positive | splash10-00xr-9510000000-28b0e365a156d2091afd | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Oxalic acid GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-0002-9000000000-538465f019815d5e1b4a | 2014-09-20 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxalic acid Quattro_QQQ 10V, Positive-QTOF (Annotated) | splash10-00di-9000000000-cb3d53cc3c40c1cbbba7 | 2012-07-25 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxalic acid Quattro_QQQ 25V, Positive-QTOF (Annotated) | splash10-0uk9-9000000000-53a009b344e3920ffca1 | 2012-07-25 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxalic acid Quattro_QQQ 40V, Positive-QTOF (Annotated) | splash10-000i-9000000000-2bafb6c472ab1030cd0f | 2012-07-25 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxalic acid EI-B (Unknown) , Positive-QTOF | splash10-0006-9000000000-8aef9a64d926571c2de0 | 2012-08-31 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxalic acid 10V, Positive-QTOF | splash10-0006-9000000000-d1ff7c94a720b1eecaf2 | 2015-04-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxalic acid 20V, Positive-QTOF | splash10-0006-9000000000-21d33d1d99d80526ee71 | 2015-04-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxalic acid 40V, Positive-QTOF | splash10-0006-9000000000-ac27102ff43446c313d3 | 2015-04-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxalic acid 10V, Negative-QTOF | splash10-000i-9000000000-fe58eaea122c39178fbe | 2015-04-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxalic acid 20V, Negative-QTOF | splash10-000i-9000000000-3850c6a7016e2874d55b | 2015-04-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxalic acid 40V, Negative-QTOF | splash10-000i-9000000000-32ac4118fe0eb9a5abb2 | 2015-04-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxalic acid 10V, Negative-QTOF | splash10-000i-9000000000-43de084d66dd1bebdeac | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxalic acid 20V, Negative-QTOF | splash10-000i-9000000000-159ed524013577f6f801 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxalic acid 40V, Negative-QTOF | splash10-0006-9000000000-d948d5d95ae14e701f57 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxalic acid 10V, Positive-QTOF | splash10-00di-9000000000-8e2d2f7a8acc88f00195 | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxalic acid 20V, Positive-QTOF | splash10-0006-9000000000-d7b47276d03e46ce72a2 | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxalic acid 40V, Positive-QTOF | splash10-0006-9000000000-a1e091bb1f5fa6e9cbc7 | 2021-09-25 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, H2O, predicted) | 2022-08-20 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, H2O, predicted) | 2022-08-20 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, H2O, predicted) | 2022-08-20 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, H2O, predicted) | 2022-08-20 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, H2O, predicted) | 2022-08-20 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, H2O, predicted) | 2022-08-20 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, H2O, predicted) | 2022-08-20 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, H2O, predicted) | 2022-08-20 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, H2O, predicted) | 2022-08-20 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, H2O, predicted) | 2022-08-20 | Wishart Lab | View Spectrum |
IR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M-H]-) | 2023-02-03 | FELIX lab | View Spectrum | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+H]+) | 2023-02-03 | FELIX lab | View Spectrum | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+Na]+) | 2023-02-03 | FELIX lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | - Blood
- Feces
- Saliva
- Sweat
- Urine
|
---|
Tissue Locations | - Bladder
- Epidermis
- Eye Lens
- Fibroblasts
- Intestine
- Kidney
- Liver
- Pancreas
- Placenta
- Testis
|
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Detected and Quantified | 6.43 +/- 1.06 uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 22.2 uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 9.2 +/- 2.7 uM | Adult (>18 years old) | Male | Normal | | details | Blood | Detected and Quantified | 3.33 +/- 1.11 uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 3.333 +/- 1.111 uM | Adult (>18 years old) | Both | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Sweat | Detected but not Quantified | Not Quantified | Adult | Both | Normal | | details | Urine | Detected and Quantified | 8.2 (3.9-14.0) umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 3.26 +/- 9.04 umol/mmol creatinine | Infant (0-1 year old) | Both | Normal | | details | Urine | Detected and Quantified | 1.11-33.34 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 6.2-13 umol/mmol creatinine | Adult (>18 years old) | Female | Normal | | details | Urine | Detected and Quantified | <52.55 umol/mmol creatinine | Children (1 - 18 years old) | Both | Normal | | details | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | <50.229 umol/mmol creatinine | Infant (0-1 year old) | Male | Normal | | details | Urine | Detected and Quantified | 18.4 +/- 6.5 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | <= 30.0 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 0-0.8 umol/mmol creatinine | Infant (0-1 year old) | Female | Normal | | details | Urine | Detected and Quantified | 0-2.8 umol/mmol creatinine | Infant (0-1 year old) | Male | Normal | | details | Urine | Detected and Quantified | 0-3.5 umol/mmol creatinine | Infant (0-1 year old) | Male | Normal | | details | Urine | Detected and Quantified | 0-6.4 umol/mmol creatinine | Infant (0-1 year old) | Female | Normal | | details | Urine | Detected and Quantified | 7.7-10 umol/mmol creatinine | Adult (>18 years old) | Male | Normal | | details | Urine | Detected and Quantified | 0-101 umol/mmol creatinine | Children (1-13 years old) | Both | Normal | | details |
|
---|
Abnormal Concentrations |
---|
| |
Blood | Detected and Quantified | 47.2 +/- 22.9 uM | Adult (>18 years old) | Both | Hemodialysis | | details | Blood | Detected and Quantified | 16.9 +/- 10.5 uM | Adult (>18 years old) | Both | Hemodialysis | | details | Blood | Detected and Quantified | 43.32 +/- 6.66 uM | Adult (>18 years old) | Both | uremia | | details | Blood | Detected and Quantified | 37.310-243.200 uM | Children (1-13 years old) | Both | Primary hyperoxaluria I | | details | Blood | Detected and Quantified | 54.444 +/- 15.556 uM | Adult (>18 years old) | Both | Uremia | | details | Urine | Detected and Quantified | 84.134 umol/mmol creatinine | Infant (0-1 year old) | Male | Fumarase deficiency | | details | Urine | Detected and Quantified | 651.333 umol/mmol creatinine | Adult (>18 years old) | Male | Primary hyperoxaluria I | | details | Urine | Detected and Quantified | 629.333-1636 umol/mmol creatinine | Children (1-13 years old) | Both | Primary hyperoxaluria I | | details | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Bladder cancer | | details | Urine | Detected and Quantified | >101 umol/mmol creatinine | Children (1-13 years old) | Both | Glycolic aciduria | | details |
|
---|
Associated Disorders and Diseases |
---|
Disease References | Hemodialysis |
---|
- Ogawa Y, Machida N, Jahana M, Gakiya M, Chinen Y, Oda M, Morozumi M, Sugaya K: Major factors modulating the serum oxalic acid level in hemodialysis patients. Front Biosci. 2004 Sep 1;9:2901-8. [PubMed:15353324 ]
| Uremia |
---|
- Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A: Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012 Jul;23(7):1258-70. doi: 10.1681/ASN.2011121175. Epub 2012 May 24. [PubMed:22626821 ]
- Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, Sinelnikov I, Krishnamurthy R, Eisner R, Gautam B, Young N, Xia J, Knox C, Dong E, Huang P, Hollander Z, Pedersen TL, Smith SR, Bamforth F, Greiner R, McManus B, Newman JW, Goodfriend T, Wishart DS: The human serum metabolome. PLoS One. 2011 Feb 16;6(2):e16957. doi: 10.1371/journal.pone.0016957. [PubMed:21359215 ]
- Shoemaker JD, Elliott WH: Automated screening of urine samples for carbohydrates, organic and amino acids after treatment with urease. J Chromatogr. 1991 Jan 2;562(1-2):125-38. [PubMed:2026685 ]
- Hoppe B, Kemper MJ, Hvizd MG, Sailer DE, Langman CB: Simultaneous determination of oxalate, citrate and sulfate in children's plasma with ion chromatography. Kidney Int. 1998 May;53(5):1348-52. [PubMed:9573551 ]
- Bouatra S, Aziat F, Mandal R, Guo AC, Wilson MR, Knox C, Bjorndahl TC, Krishnamurthy R, Saleem F, Liu P, Dame ZT, Poelzer J, Huynh J, Yallou FS, Psychogios N, Dong E, Bogumil R, Roehring C, Wishart DS: The human urine metabolome. PLoS One. 2013 Sep 4;8(9):e73076. doi: 10.1371/journal.pone.0073076. eCollection 2013. [PubMed:24023812 ]
- Ogawa Y, Machida N, Jahana M, Gakiya M, Chinen Y, Oda M, Morozumi M, Sugaya K: Major factors modulating the serum oxalic acid level in hemodialysis patients. Front Biosci. 2004 Sep 1;9:2901-8. [PubMed:15353324 ]
- Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W: Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003 May;63(5):1934-43. doi: 10.1046/j.1523-1755.2003.00924.x. [PubMed:12675874 ]
- (). Merck Manual of Diagnosis and Therapy. . . [ISBN:978-0-911910-19-3 ]
- (). David F. Putnam Composition and Concentrative Properties of Human Urine. NASA Contractor Report. July 1971. .
- (). Geigy Scientific Tables, 8th Rev edition, pp. 130. Edited by C. Lentner, West Cadwell, N.J.: Medical education Div., Ciba-Geigy Corp. Basel, Switzerland c1981-1992.. .
- (). Geigy Scientific Tables, 8th Rev edition, pp. 165-177. Edited by C. Lentner, West Cadwell, N.J.: Medical education Div., Ciba-Geigy Corp., Basel, Switzerland c1981-1992.. .
| Primary hyperoxaluria I |
---|
- Holmgren G, Hornstrom T, Johansson S, Samuelson G: Primary hyperoxaluria (glycolic acid variant): a clinical and genetical investigation of eight cases. Ups J Med Sci. 1978;83(1):65-70. [PubMed:705974 ]
| Fumarase deficiency |
---|
- Bastug O, Kardas F, Ozturk MA, Halis H, Memur S, Korkmaz L, Tag Z, Gunes T: A rare cause of opistotonus; fumaric aciduria: The first case presentation in Turkey. Turk Pediatri Ars. 2014 Mar 1;49(1):74-6. doi: 10.5152/tpa.2014.442. eCollection 2014 Mar. [PubMed:26078636 ]
| Glycolic aciduria |
---|
- Coulter-Mackie MB, White CT, Lange D, et al. (2002). Primary Hyperoxaluria Type 1. 2002 Jun 19 [Updated 2014 Jul 17]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1283/. University of Washington, Seattle.
|
|
---|
Associated OMIM IDs | |
---|
External Links |
---|
DrugBank ID | DB03902 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | FDB031074 |
---|
KNApSAcK ID | C00001198 |
---|
Chemspider ID | 946 |
---|
KEGG Compound ID | C00209 |
---|
BioCyc ID | OXALATE |
---|
BiGG ID | 34265 |
---|
Wikipedia Link | Oxalic_acid |
---|
METLIN ID | 113 |
---|
PubChem Compound | 971 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 16995 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | OXA |
---|
MarkerDB ID | MDB00000389 |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Download (PDF) |
---|
General References | - Amoroso A, Pirulli D, Florian F, Puzzer D, Boniotto M, Crovella S, Zezlina S, Spano A, Mazzola G, Savoldi S, Ferrettini C, Berutti S, Petrarulo M, Marangella M: AGXT gene mutations and their influence on clinical heterogeneity of type 1 primary hyperoxaluria. J Am Soc Nephrol. 2001 Oct;12(10):2072-9. [PubMed:11562405 ]
- Pirulli D, Marangella M, Amoroso A: Primary hyperoxaluria: genotype-phenotype correlation. J Nephrol. 2003 Mar-Apr;16(2):297-309. [PubMed:12768081 ]
- de O G Mendonca C, Martini LA, Baxmann AC, Nishiura JL, Cuppari L, Sigulem DM, Heilberg IP: Effects of an oxalate load on urinary oxalate excretion in calcium stone formers. J Ren Nutr. 2003 Jan;13(1):39-46. [PubMed:12563622 ]
- Singh S, Tai C, Ganz G, Yeung CK, Magil A, Rosenberg F, Applegarth D, Levin A: Steroid-responsive pleuropericarditis and livedo reticularis in an unusual case of adult-onset primary hyperoxaluria. Am J Kidney Dis. 1999 Apr;33(4):e5. [PubMed:10196036 ]
- Astarcioglu I, Karademir S, Gulay H, Bora S, Astarcioglu H, Kavukcu S, Turkmen M, Soylu A: Primary hyperoxaluria: simultaneous combined liver and kidney transplantation from a living related donor. Liver Transpl. 2003 Apr;9(4):433-6. [PubMed:12682898 ]
- Selvam R, Kalaiselvi P: A novel basic protein from human kidney which inhibits calcium oxalate crystal growth. BJU Int. 2000 Jul;86(1):7-13. [PubMed:10886075 ]
- Kwak C, Jeong BC, Kim HK, Kim EC, Chox MS, Kim HH: Molecular epidemiology of fecal Oxalobacter formigenes in healthy adults living in Seoul, Korea. J Endourol. 2003 May;17(4):239-43. [PubMed:12816588 ]
- Vicanova J, Boelsma E, Mommaas AM, Kempenaar JA, Forslind B, Pallon J, Egelrud T, Koerten HK, Ponec M: Normalization of epidermal calcium distribution profile in reconstructed human epidermis is related to improvement of terminal differentiation and stratum corneum barrier formation. J Invest Dermatol. 1998 Jul;111(1):97-106. [PubMed:9665394 ]
- Mydlik M, Derzsiova K, Pribylincova V, Reznicek J: [Urinary oxalic acid excretion in chronic kidney failure and after kidney transplantation]. Vnitr Lek. 1996 Dec;42(12):813-7. [PubMed:9072879 ]
- Mizusawa Y, Parnham AP, Falk MC, Burke JR, Nicol D, Yamanaka J, Lynch SV, Strong RW: Potential for bilateral nephrectomy to reduce oxalate release after combined liver and kidney transplantation for primary hyperoxaluria type 1. Clin Transplant. 1997 Oct;11(5 Pt 1):361-5. [PubMed:9361924 ]
- Pecorella I, McCartney AC, Lucas S, Michaels L, Ciardi A, Di Tondo U, Garner A: Histological study of oxalosis in the eye and adnexa of AIDS patients. Histopathology. 1995 Nov;27(5):431-8. [PubMed:8575733 ]
- Huang MY, Chaturvedi LS, Koul S, Koul HK: Oxalate stimulates IL-6 production in HK-2 cells, a line of human renal proximal tubular epithelial cells. Kidney Int. 2005 Aug;68(2):497-503. [PubMed:16014026 ]
- Shapiro R, Weismann I, Mandel H, Eisenstein B, Ben-Ari Z, Bar-Nathan N, Zehavi I, Dinari G, Mor E: Primary hyperoxaluria type 1: improved outcome with timely liver transplantation: a single-center report of 36 children. Transplantation. 2001 Aug 15;72(3):428-32. [PubMed:11502971 ]
- Motoyoshil Y, Hattori M, Chikamoto H, Nakakura H, Furue T, Miyakawa S, Kohno M, Ito K, Kai K, Nakajima I, Fuchinoue S, Teraoka S, Akiba T, Kitayama H, Wada N, Ogawa Y: [Sequential combined liver-kidney transplantation for a one-year-old boy with infantile primary hyperoxaluria type 1]. Nihon Jinzo Gakkai Shi. 2006;48(1):22-8. [PubMed:16480063 ]
- de Water R, Noordermeer C, van der Kwast TH, Nizze H, Boeve ER, Kok DJ, Schroder FH: Calcium oxalate nephrolithiasis: effect of renal crystal deposition on the cellular composition of the renal interstitium. Am J Kidney Dis. 1999 Apr;33(4):761-71. [PubMed:10196021 ]
- van Woerden CS, Groothof JW, Wanders RJ, Waterham HR, Wijburg FR: [From gene to disease; primary hyperoxaluria type I caused by mutations in the AGXT gene]. Ned Tijdschr Geneeskd. 2006 Jul 29;150(30):1669-72. [PubMed:16922352 ]
- Robertson WG: Renal stones in the tropics. Semin Nephrol. 2003 Jan;23(1):77-87. [PubMed:12563603 ]
- Nakagawa Y, Abram V, Parks JH, Lau HS, Kawooya JK, Coe FL: Urine glycoprotein crystal growth inhibitors. Evidence for a molecular abnormality in calcium oxalate nephrolithiasis. J Clin Invest. 1985 Oct;76(4):1455-62. [PubMed:4056037 ]
- Massey LK, Palmer RG, Horner HT: Oxalate content of soybean seeds (Glycine max: Leguminosae), soyfoods, and other edible legumes. J Agric Food Chem. 2001 Sep;49(9):4262-6. [PubMed:11559120 ]
- Petrarulo M, Vitale C, Facchini P, Marangella M: Biochemical approach to diagnosis and differentiation of primary hyperoxalurias: an update. J Nephrol. 1998 Mar-Apr;11 Suppl 1:23-8. [PubMed:9604805 ]
- Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A: Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012 Jul;23(7):1258-70. doi: 10.1681/ASN.2011121175. Epub 2012 May 24. [PubMed:22626821 ]
- Konstantynowicz J, Porowski T, Zoch-Zwierz W, Wasilewska J, Kadziela-Olech H, Kulak W, Owens SC, Piotrowska-Jastrzebska J, Kaczmarski M: A potential pathogenic role of oxalate in autism. Eur J Paediatr Neurol. 2012 Sep;16(5):485-91. doi: 10.1016/j.ejpn.2011.08.004. Epub 2011 Sep 10. [PubMed:21911305 ]
- Elshenawy S, Pinney SE, Stuart T, Doulias PT, Zura G, Parry S, Elovitz MA, Bennett MJ, Bansal A, Strauss JF 3rd, Ischiropoulos H, Simmons RA: The Metabolomic Signature of the Placenta in Spontaneous Preterm Birth. Int J Mol Sci. 2020 Feb 4;21(3). pii: ijms21031043. doi: 10.3390/ijms21031043. [PubMed:32033212 ]
|
---|